General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Focused diversification

Focused diversification

Novartis strategy is based on focused diversification. Our uniquely broad business portfolio focuses on science-based healthcare sectors that are growing, reward innovation and enhance the lives of patients. Innovation is fundamental to our business. In 2012, we invested $9.1 billion (USD) across our divisions in R&D and we plan to sustain our high level of investment.

Novartis is consistently rated as having one of the industry’s most respected pharmaceutical development pipelines with 144 projects in pharmaceutical clinical development.

“A broad, diversified portfolio is going to become increasingly important as more and more payors look for low-cost generics and preventive vaccines as complements to innovative pharmaceuticals.”

Joseph Jimenez, Chief Executive Officer of Novartis.

Novartis has a long-established track record of leadership in pharmaceutical research. We also leverage this core R&D competence across our other divisions, sharing research findings and knowledge throughout our organization.

Alcon transforms eye care possibilities into therapeutic realities through the discovery and development of innovative devices and ophthalmic products. With one of the largest corporate commitments to R&D in the eye care industry, Alcon develops innovative eye care treatments based on unmet medical needs. Alcon’s pipeline is fueled by in-house development, partnerships with leading institutions, acquisitions and in-licensing. Additionally, Alcon has the opportunity to partner with the Novartis Institutes for BioMedical Research (NIBR) to accelerate product innovation for the eye.

Sandoz, the generics division of Novartis, is the world leader in biosimilars, oncology injectables, dermatology, ophthalmics, and anti-infectives that have lost patent protection. By 2018, patents are scheduled to expire on biologics with global sales of more than USD 100 billion and Sandoz is well-positioned to take full advantage of that opportunity.

Flu and the emerging meningococcal franchise will be key growth drivers for the Vaccines Division. The division also has a broad pipeline of new vaccines under development.

OTC focuses on self-care products for consumers.